Home>>Signaling Pathways>> Others>> MyD88>>IL-1R Antagonist

IL-1R Antagonist

Catalog No.GC18529

IL-1R Antagonist (compound 4a) is a low molecular weight, cell-penetrating Toll/IL-1 receptor/resistance (TIR) domain/BB-Loop mimic.

Products are for research use only. Not for human use. We do not sell to patients.

IL-1R Antagonist Chemical Structure

Cas No.: 566914-00-9

Size Price Stock Qty
1mg
$33.00
In stock
5mg
$84.00
In stock
10mg
$100.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

IL-1R antagonist is a peptide mimic of the myeloid differentiation primary response gene 88 (MyD88) that changes the interaction of MyD88 and IL-1 receptor type I (IL-1RI). In mouse lymphocytes and thymoma EL4 cells, IL-1R antagonist (>=10 μM) inhibits IL-1β-activated phosphorylation of p38 MAP kinase, a process specifically mediated by disruption of IL-1RI/MyD88. However, it has no influence on LPS-mediated TLR4/MyD88 signaling in freshly isolated mouse lymphocytes (100 μM). IL-1R antagonist also attenuates IL-1β-induced fever (200 mg/kg) and Staphylococcal enterotoxin B (SEB)-induced pro-inflammatory cytokine production and toxicity in mice at doses between 2-6 mg.[1]

Reference:
[1]. Bartfai, T., Behrens, M.M., Gaidarova, S., et al. A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses. Proc. Natl. Acad. Sci. USA 100(13), 7971-7976 (2003).

Reviews

Review for IL-1R Antagonist

Average Rating: 5 ★★★★★ (Based on Reviews and 2 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for IL-1R Antagonist

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.